What happened
The Food and Drug Administration Thursday approved a new class of pain pill that is not addictive like opioids. Suzetrigine, being sold as Journavx by Vertex Pharmaceuticals, is the first new pharmaceutical treatment for pain to win FDA approval in more than 20 years.
Who said what
Opioids work by binding to receptors in the brain that receive pain signals from nerves around the body, but "those chemical interactions also give rise to opioids' addictive effects," The Associated Press said. But while prescription opioids have helped fuel an epidemic of addiction and overdoses, suzetrigine "works differently," intercepting pain signals before they reach the brain.
In two clinical trials submitted by Vertex, suzetrigine was more effective than a placebo at treating short-term pain in people recovering from stomach and foot surgery, and on par with a combined acetaminophen-hydrocodone pill, like Vicodin.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
What next?
Journavx was approved to treat acute pain in adults. But at a list price of $15.50 a pill, it "faces some hurdles in winning over physicians, hospitals and insurance companies," The Washington Post said. The new painkiller is promising because "there are a number of people who, once they have an opioid, want an opioid constantly," University of Washington pain expert Dr. John Loeser said to The New York Times. But acetaminophen-opioid pills are "dirt cheap."
-
The UK’s opioid crisis: why the stats don’t add upThe Explainer A new report has revealed that the UK’s total of opioid-related deaths could be much greater than official figures show
-
Gaza genocide: will UN ruling change anything?Today's Big Question Commission of Inquiry’s findings ‘give unprecedented weight’ to genocide claims
-
How The Summer I Turned Pretty has brought out the worst in its fansIn the Spotlight Amazon’s love-triangle hit ‘driving some of the most bonkers and unhinged online energy in the history of the internet’
-
The UK’s opioid crisis: why the stats don’t add up
The Explainer A new report has revealed that the UK’s total of opioid-related deaths could be much greater than official figures show
-
Quit-smoking ads are being put outUnder the radar The dissolution of a government-funded campaign could lead to more smokers in the future
-
Sloth fever shows no signs of slowing downThe explainer The vector-borne illness is expanding its range
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Forever chemicals were found in reusable menstrual products. That is nothing new for women.Under the Radar Toxic chemicals are all too common in such products
-
Why the FDA wants to restrict kratom-related productsIn the Spotlight The compound is currently sold across the United States
-
Not just a number: how aging rates vary by countryThe explainer Inequality is a key factor
